Takeshi Sugimoto

Dr. Takeshi Sugimoto

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Advances in Hematology
Verified
Journal Article
Open access
PDF file
SOShinya Ohata
Shinya Ohata
KTKei Takenaka
Kei Takenaka
DSDaisuke Sugiyama
Daisuke Sugiyama
Takeshi SugimotoTakeshi Sugimoto
Takeshi Sugimoto
Background. Bone marrow infiltration of lymphoma cells is a candidate risk factor for infusion-related reactions (IRRs) in patients with CD20-positive B-cell non-Hodgkin lymphoma (B-NHL). However, despite with the lack of sufficient data, the effect of bone marrow infiltration of B-NHL cells on the incidence rate of grade 2 or higher IRRs with the administration of rituximab has been retrospectively studied in this paper. Methods. Patients with CD20-positive B-NHL who received the rituximab induction therapy for the first time were enrolled in this study. To evaluate the bone marrow infiltration of B-NHL cells, MayGiemsa stain of bone marrow films and flow cytometry examination of bone marrow aspiration samples were performed. IRR grade was determined using the IRR criteria in the Common Terminology Criteria for Adverse Events version 4.0. Results. A total of 127 patients were eligible for this study. Grade 2 or higher IRRs were observed in 43 (34) patients. In univariate analysis, use of glucocorticoid before rituximab infusion was a strong risk-avoiding factor for grade 2 or higher IRRs. Advanced stage of disease (Ann Arbor: stages III and IV) or bone marrow infiltration of B-NHL cells revealed the risk factors, regardless of glucocorticoid premedication. Using multivariate analysis, bone marrow infiltration was found to be an independent risk factor for patients without prior glucocorticoid use. Conclusion. Bone marrow infiltration of B-NHL cells is a risk factor for grade 2 or higher IRRs at the first rituximab induction therapy without glucocorticoid premedication.

1 January 2005 in GEOCHEMICAL JOURNAL
Verified
Journal Article
Open access
Takeshi SugimotoTakeshi Sugimoto
Takeshi Sugimoto
HIHidemi Ishibashi
Hidemi Ishibashi
SWSadatsugu Wakamatsu
Sadatsugu Wakamatsu
TYTakeru Yanagi
Takeru Yanagi
The volcanic history of the Shimabara Peninsula, Kyushu, Japan, is divided into two stages; Pre-Unzen volcano stage (4 Ma-500 ka) and Unzen volcano stage (500 ka-present). Pre-Unzen volcanic rocks comprise olivine basalt and two- pyroxene andesite lava flows and pyroclastics. The similarity of trace elements chemistry indicates that Pre-Unzen basalts evolved from different primary magmas originated in the same mantle source. They were differentiated by olivine-domi- nant fractional crystallization and crustal assimilation. This process produced parental magmas for Pre-Unzen andesite. The evolution of Pre-Unzen andesites can be explained by the combination of plagioclase + pyroxenes + magnetite frac- tional crystallization and crustal assimilation. Unzen volcanic rocks are composed of hornblende andesite to dacite lava domes, lava flows and pyroclastics. They have petrographical and geochemical features indicating that they were pro- duced by magma mixing. Mafic inclusions are commonly included in Unzen volcanic rocks and show evidence of hybridi- zation between aphyric basalt and phenocryst-rich dacite magma in various ratios. The existence of mafic inclusions with positive Nb anomalies in spidergram indicates an injection of ocean-island type basaltic magmas. The estimated mafic endmember for the dacite magma is an evolved basalt with MgO = 5.5 wt.%. This corresponds to the most evolved composition of the Pre-Unzen basalt and suggests continuous basaltic magma plumbing system throughout the eruptive history of the Shimabara peninsula.

4 February 2023 in Cancer Genetics
Verified
Journal Article
Closed access
KYKatsuya Yamamoto
Katsuya Yamamoto
HMHisayuki Matsumoto
Hisayuki Matsumoto
SMSakuya Matsumoto
Sakuya Matsumoto
RSRina Sakai
Rina Sakai
AKAkihito Kitao
Akihito Kitao
HMHironobu Minami
Hironobu Minami

4 September 2017 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
STSaki Todo
Saki Todo
KOKohei Okamoto
Kohei Okamoto
Takeshi SugimotoTakeshi Sugimoto
Takeshi Sugimoto
TTToshimasa Takahashi
Toshimasa Takahashi
YNYasushi Nakagawa
Yasushi Nakagawa
KYKoichi Yokono
Koichi Yokono
An 80-year-old female was admitted to our hospital due to malaise. The initial diagnosis on admission was pernicious anemia (PA), Hashimoto thyroiditis and autoimmune atrophic gastritis. Autoimmune hemolytic anemia was suspected because direct antiglobulin test (DAT) was positive. Treatment with vitamin B12 improved anemia, with the disappearance of hemolysis. In some cases, PA patients with positive DAT may have hemolysis without the involvement of the autoimmune mechanism. Therefore, it is important to carefully assess PA patients with hemolysis and positive DAT for the prevention of unnecessary administration of steroid therapy.

1 June 1991 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
NHN. Hirawa
N. Hirawa
Yoshinari UeharaYoshinari Uehara
Yoshinari Uehara
ANA. Numabe
A. Numabe
TIT. Ikeda
T. Ikeda
SYS. Yagr
S. Yagr
MIM. Ishii
M. Ishii

19 January 2022 in Practical Laboratory Medicine
Verified
Journal Article
Open access
SSSyuichiro Saito
Syuichiro Saito
Takeshi SugimotoTakeshi Sugimoto
Takeshi Sugimoto
KTKei Takenaka
Kei Takenaka
HGHideaki Goto
Hideaki Goto
AKAkira Kumahara
Akira Kumahara
KTKiyonobu Takatsuki
Kiyonobu Takatsuki
Co-administration of Piperacillin/Tazobactam (PIPC/TAZ) and Vancomycin (VCM) as an antibiotic therapy for severe infectious diseases increases the risk of nephrotoxicity. We retrospectively investigated the utility of monitoring VCM trough concentration in early stage of developing acute kidney injury (AKI) on this combination therapy. We enrolled all infectious disease patients who were managed with concurrent PIPC/TAZ and VCM. The record of dosage and the administration interval of each antibiotic and its clinical parameters, as well as the VCM trough concentrations, blood culture for bacteria, and serum creatinine values, were collected. VCM trough concentration was measured during the initial 48–72 h of VCM administration. Nephrotoxicity was evaluated as the degree of AKI. A total of 47 patients fulfilling the criteria were registered, and AKI developed in 10 patients. There was no statistical difference between the AKI and non-AKI groups with regard to age, height, weight, basal creatinine level, body surface area, body mass index, PIPC/TAZ dose, VCM dose, gender, artificial management, and death within around 30 days. The VCM trough level was increased significantly in the AKI group (mean [standard deviation {SD}]: 25.9 [7.8] μg/mL) compared to that in the non-AKI group (mean [SD]: 15.7 [6.9] μg/mL) (p = 0.003). During the clinical course, renal function returned to normal levels in three out of four AKI stage 2 patients, whereas only partial recovery was achieved in all AKI stage 3 patients. A high VCM trough concentration may have an influence on the occurrence of AKI during combination therapy of PIPC/TAZ and VCM. Careful monitoring of VCM trough concentration will be required to prevent AKI progression.